ITPR2 and cancer: Out of these, we have chosen three most changed in LSCCs namely RGS5 (fold change 0.08), MAF (fold change 0.15), and ITPR2 (fold change 0.3) which are attractive candidates for novel tumor suppressors according to their function and involvement in other cancers (Fig 1C).